AR080585A1 - Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias - Google Patents

Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias

Info

Publication number
AR080585A1
AR080585A1 ARP110100809A ARP110100809A AR080585A1 AR 080585 A1 AR080585 A1 AR 080585A1 AR P110100809 A ARP110100809 A AR P110100809A AR P110100809 A ARP110100809 A AR P110100809A AR 080585 A1 AR080585 A1 AR 080585A1
Authority
AR
Argentina
Prior art keywords
tumor
protein
tumors
antigen
proteins
Prior art date
Application number
ARP110100809A
Other languages
English (en)
Inventor
Thomas Hiller
Jens Schumacher
Thorsten Klamp
Ugur Sahin
Ozlem Tureci
Michael Koslowski
Original Assignee
Universitaetsmedizin Der Johannes Gutenberg Uni Mainz
Biontech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10002775A external-priority patent/EP2366709A1/en
Application filed by Universitaetsmedizin Der Johannes Gutenberg Uni Mainz, Biontech Ag filed Critical Universitaetsmedizin Der Johannes Gutenberg Uni Mainz
Publication of AR080585A1 publication Critical patent/AR080585A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2730/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se relaciona con la inmunoterapia de los tumores, particularmente con la vacunacion contra los tumores, mediante el uso de proteínas quiméricas que comprenden la totalidad o una porcion de la proteína antigénica principal del virus de la hepatitis B y una secuencia de aminoácidos que comprende un epítope derivado de una porcion extracelular de un antígeno asociado a un tumor. En particular, se proveen partículas similares a virus que comprenden dichas proteínas quiméricas para provocar una respuesta inmune humoral en un sujeto contra el antígeno asociado al tumor, particularmente contra las células que contienen dicho antígeno asociado a un tumor en su superficie, donde el antígeno asociado al tumor es una proteína propia de dicho sujeto. Proteína. Vector. Acido nucleico. Composicion inmunologica. Reivindicacion 3: La proteína de la reivindicacion 1 o 2, caracterizada porque el antígeno asociado al tumor es una proteína de la familia de la claudina o PLAC1, donde la proteína de la familia de la claudina preferiblemente se selecciona del grupo que consiste en CLDN18.2 y CLDN6.
ARP110100809A 2010-03-16 2011-03-14 Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias AR080585A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10002775A EP2366709A1 (en) 2010-03-16 2010-03-16 Tumor vaccination involving a humoral immune response against self-proteins
EP10016216 2010-12-30

Publications (1)

Publication Number Publication Date
AR080585A1 true AR080585A1 (es) 2012-04-18

Family

ID=43855962

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100809A AR080585A1 (es) 2010-03-16 2011-03-14 Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias

Country Status (9)

Country Link
US (3) US8840902B2 (es)
EP (1) EP2547695B1 (es)
JP (2) JP6199036B2 (es)
AR (1) AR080585A1 (es)
AU (1) AU2011229518B2 (es)
CA (1) CA2786940C (es)
ES (1) ES2675825T3 (es)
TR (1) TR201809413T4 (es)
WO (1) WO2011113546A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
AU2011229518B2 (en) 2010-03-16 2015-09-24 Biontech Protein Therapeutics Gmbh Tumor vaccination involving a humoral immune response against self-proteins
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
NZ746691A (en) 2012-11-13 2020-08-28 Astellas Pharma Inc Agents for treatment of claudin expressing cancer diseases
PT3126381T (pt) * 2014-04-01 2019-04-18 Ganymed Pharmaceuticals Ag Imunorrecetores e epítopos de células t específicos da claudina-6
CN104293741A (zh) * 2014-10-10 2015-01-21 武汉大学 一种呼吸道合胞病毒病毒样颗粒疫苗及其制备方法和应用
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
CA3056819A1 (en) 2017-03-24 2018-09-27 Biontech Rna Pharmaceuticals Gmbh Methods and compositions for stimulating immune response
CA3089653A1 (en) 2018-03-08 2019-09-12 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
DK3941946T3 (da) 2019-03-20 2025-03-24 Univ California Claudin-6-antistoffer og lægemiddelkonjugater
KR20220010500A (ko) * 2019-05-20 2022-01-25 비온테크 에스이 난소암 치료용 rna
AU2021388650A1 (en) * 2020-11-27 2023-06-22 Sunshine Lake Pharma Co., Ltd. Cldn18.2 antibody and use thereof
CN114836388A (zh) * 2022-06-07 2022-08-02 江苏亲科生物研究中心有限公司 Claudin18.2单克隆抗体及其制备方法和用途
AU2024274880A1 (en) 2023-05-25 2026-01-15 The Regents Of The University Of California Methods of treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
AU2540897A (en) * 1996-03-21 1997-10-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chimeric polypeptides for tumor antigen vaccines
ES2269371T3 (es) * 2000-04-07 2007-04-01 University Of Leeds Proteinas de fusion con el antigeno de la nucleocapsida de la hepatitis b.
DE60234375D1 (de) * 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP5022028B2 (ja) 2003-03-26 2012-09-12 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト メラン−ａペプチドアナログ−ウイルス様粒子コンジュゲート
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2009033276A1 (en) * 2007-09-11 2009-03-19 UNIVERSITé LAVAL Malva mosaic virus and virus-like particles and uses thereof
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
WO2010094499A1 (en) * 2009-02-20 2010-08-26 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
CN101584860A (zh) * 2009-04-27 2009-11-25 西安杰诺瓦生物科技有限公司 重组人Claudin18.2肿瘤疫苗及其制备方法
AU2011229518B2 (en) 2010-03-16 2015-09-24 Biontech Protein Therapeutics Gmbh Tumor vaccination involving a humoral immune response against self-proteins

Also Published As

Publication number Publication date
US8840902B2 (en) 2014-09-23
US20170072035A1 (en) 2017-03-16
US10526387B2 (en) 2020-01-07
TR201809413T4 (tr) 2018-07-23
AU2011229518A1 (en) 2012-08-30
CA2786940C (en) 2019-09-24
AU2011229518B2 (en) 2015-09-24
CA2786940A1 (en) 2011-09-22
JP2017025057A (ja) 2017-02-02
US20150152154A1 (en) 2015-06-04
US9617321B2 (en) 2017-04-11
ES2675825T3 (es) 2018-07-12
WO2011113546A1 (en) 2011-09-22
JP6199036B2 (ja) 2017-09-20
JP2013521785A (ja) 2013-06-13
EP2547695A1 (en) 2013-01-23
US20130052217A1 (en) 2013-02-28
EP2547695B1 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
AR080585A1 (es) Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias
MX389568B (es) Péptidos y uso de los mismos en inmunoterapia contra varios tumores, tales como cáncer de pulmón, que incluye cáncer de pulmón de células no pequeñas (nsclc)
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
WO2010104749A3 (en) Antigen presenting cell targeted cancer vaccines
WO2010104761A3 (en) Anti-cd40 antibodies and uses thereof
PH12015500308B1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
WO2014004385A3 (en) Anti-cancer vaccines
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
EA201400216A1 (ru) Консервирование биологических продуктов, в частности вакцин, с применением вакуума
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
MX2019007924A (es) Vacunas contra la influenza.
WO2012038832A3 (en) Generation of replicating chimeric measles virus - retrovirus particles
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
MX351642B (es) Vacuna para virus de leucemia felina recombinante que contiene gen de envoltura del virus de leucemia felina optimizado.
MX2009011851A (es) Plasmidos de dna que tienen expresion y estabilidad mejoradas.
MX365656B (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
MX2016009952A (es) Proteinas y antigenos del virus de diarrea epidemica porcino (pedv).
WO2012178078A3 (en) Use of yscf, truncated yscf and yscf homologs as adjuvants
AR105134A1 (es) Vacunas contra la influenza con coincidencia antigénica
MY193910A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MY194241A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC
MY194653A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
AR085907A2 (es) Peptidos adyuvantes de vacunas mucosales, proteina quimerica, composiciones de vacuna que la comprenden y uso para la preparacion de vacunas

Legal Events

Date Code Title Description
FG Grant, registration